Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has received a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) saw unusually large options trading on Thursday. Stock traders acquired 4,281 call options on the company. This is an increase of approximately 3,071% compared to the average volume of 135 call options. YMAB has been the topic of a number of research analyst reports. JPMorgan Chase & Co. […]